...
首页> 外文期刊>Frontiers in Endocrinology >TR4 Nuclear Receptor Different Roles in Prostate Cancer Progression
【24h】

TR4 Nuclear Receptor Different Roles in Prostate Cancer Progression

机译:TR4核受体在前列腺癌进展中的不同作用

获取原文

摘要

Nuclear receptors are important to maintain the tissue homeostasis. Each receptor is tightly controlled and under a very complicated balance. In this review, we summarize the current findings regarding the nuclear receptor TR4 and its role in prostate cancer (PCa) progression. In general, TR4 can inhibit the PCa carcinogenesis. However, when PPARγ is knocked out, activation of TR4 can have an opposite effect to promote the PCa carcinogenesis. Clinical data also indicates that higher TR4 expression is found in PCa tissues with high Gleason scores compared to those tissues with low Gleason scores. In vitro and in vivo studies show that TR4 can promote PCa progression. Mechanism dissection indicates that TR4 inhibits PCa carcinogenesis through regulating the tumor suppressor ATM to reduce DNA damages. On the other hand, in the absence of PPARγ, TR4 tends to increase the stem cell population and epithelial–mesenchymal transition (EMT) via regulating CCL2, Oct4, EZH2, and miRNA-373-3p expression that results in increased PCa carcinogenesis. In opposition to PCa initiation, TR4 can increase PCa metastasis via modulating the CCL2 signals. Finally, targeting TR4 enhances the chemotherapy and radiation therapy sensitivity in PCa. Together, these data suggest TR4 is a key player to control PCa progression, and targeting TR4 with small molecules may provide us a new and better therapy to suppress PCa progression.
机译:核受体对于维持组织动态平衡很重要。每个受体都受到严格控制,并且处于非常复杂的平衡之下。在这篇综述中,我们总结了有关核受体TR4及其在前列腺癌(PCa)进展中的作用的当前发现。通常,TR4可以抑制PCa癌变。但是,当敲除PPARγ时,TR4的激活可能具有相反的作用来促进PCa癌变。临床数据还表明,与那些具有较低Gleason分数的组织相比,在具有较高Gleason分数的PCa组织中发现了更高的TR4表达。体外和体内研究表明,TR4可以促进PCa进程。机制解剖表明,TR4通过调节肿瘤抑制因子ATM减少DNA损伤来抑制PCa癌变。另一方面,在缺乏PPARγ的情况下,TR4倾向于通过调节CCL2,Oct4,EZH2和miRNA-373-3p的表达来增加PCa的致癌作用,从而增加干细胞的数量和上皮-间质转化(EMT)。与PCa启动相反,TR4可以通过调节CCL2信号来增加PCa转移。最后,靶向TR4可增强PCa的化学疗法和放射疗法敏感性。总之,这些数据表明TR4是控制PCa进程的关键因素,而以小分子靶向TR4可能为我们提供抑制PCa进程的新的更好的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号